Industry News
HPV4 Vaccine Sage For Adolescents And Young Women In Routine Clinical Care
Oct 03, 2012
A study of almost 200,000 young females who received the quadrivalent human papilloma virus (HPV4) vaccine found that immunization was associated only with same-day syncope (fainting) and skin infections in the two weeks after vaccination... Read More
Erbitux Outcomes In Patients With Head And Neck Cancer Seem To Be Independent Of HPV Tumor Status
Oct 03, 2012
Merck Serono, a division of Merck, Darmstadt, Germany, today announced new data from the randomized Phase III EXTREME trial of Erbitux® (cetuximab) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), presented at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 - October 2, 2012... Read More
Renal Cell Carcinoma Phase III Data
Oct 03, 2012
New trial results on pazopanib and temsirolimus have important implications for patients New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna... Read More
The Challenges Of Managing Blood Clotting In Cancer Patients
Oct 03, 2012
New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, comments Dr... Read More
Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option
Oct 03, 2012
Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with the only approved licensed treatment combination, lapatinib and capecitabine, (30.9 months vs. 25.1 months, HR=0.682; P=0... Read More
Study Opens A New Door To More Personalized Treatment Of Advanced Breast Cancer
Oct 03, 2012
For the first time, researchers have conducted a large trial in which they tested the entire genome of individual breast cancers to help personalize treatment. They released their findings at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. In recent years, a number of drugs have been developed that target specific genetic alterations in cancer... Read More
Optimal Duration Of Trastuzumab Therapy For Women With HER2+ Early Breast Cancer: New Findings
Oct 03, 2012
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna... Read More
Rheumatoid Arthritis Tied To Raised Risk Of Blood Clots
Oct 03, 2012
A new study from Sweden suggests that patients with rheumatoid arthritis may be at higher risk for blood clots in the first ten years after diagnosis compared to the general population... Read More
Treating Kaposi Sarcoma Using A Sugar-Free Approach
Oct 03, 2012
A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans... Read More
New Vaccinia Virus Shows Potential For Treating Triple-Negative Breast Cancer
Oct 03, 2012
Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City have shown that a new vaccinia virus, acting as both an oncolytic and anti-angiogenic agent, can enter and kill triple-negative breast cancer (TNBC) cells... Read More
Previous Page Next Page